OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is a clinical stage biopharmaceutical company that develops cancer immunotherapy products. The company has proprietary rights to a breast and prostate patent vaccine; and a process for the growth of cancer cells and targeted chemotherapies. Its lead product is ProscaVax that is in the planning stage of a Phase II clinical trial for the treatment of prostate cancer. The company also has a portfolio of targeted therapies. OncBioMune Pharmaceuticals, Inc. is headquartered in Baton Rouge, Louisiana.
The company recently hit the market with news that the 20 patient enrollment has been completed in the Company’s Phase 1 clinical trial of ProscaVax as a novel vaccine treatment for prostate cancer. According to the release, in the study, ProscaVax is being evaluated for safety, tolerability and efficacy in prostate specific antigen (PSA) progressing prostate cancer in hormone-naïve and hormone-independent patients. ProscaVax is an immunotherapeutic cancer vaccine consisting of a combination of the tumor-associated antigen PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).
OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is a clinical stage biopharmaceutical company that develops cancer immunotherapy products.
The company has proprietary rights to a breast and prostate patent vaccine; and a process for the growth of cancer cells and targeted chemotherapies. Its lead product is ProscaVax that is in the planning stage of a Phase II clinical trial for the treatment of prostate cancer.
The Lay of the Land
One point we would not want to overlook is the fact that OBMP could conceivably be an easy fit for a few different names as far as a take-out candidate.
Just starting with those in the space who have shown a clear interest in development or acquisition of assets that offer potential for market share in the prostate cancer segment, one can easily point to the likes of three different Nasdaq-listed biotechs: Seattle Genetics, Inc. (SGEN), Inovio Pharmaceuticals (INO), Nymox Pharmaceutical Corporation (NYMX).
Each has the balance sheet, and each could swallow up OBMP without burping and likely find some boost in value through synergies and outcome distribution.
OBMP management has made several moves in recent weeks to diversify the outcome distribution of its investment portfolio by adding proven, revenue-generating products to its stable of assets.
The company first announced the acquisition of Vitel Laboratorios, S.A. de C.V, which is expected to “transform OncBioMune into a revenue-generating international pharmaceutical company with a more diverse product line with a particularly deep reach throughout Mexico, Central and Latin America, and relationships across Europe and Asia.” The acquisition of Vitel includes two drugs it licenses and sells in Mexico, Bekunis for constipation and Cirkused for stress.
“We are very excited by the initial sales of Bekunis and Cirkused and the fact that they handily exceeded our expectations subsequent to launch, an often challenging time to capture market,” commented Manuel Cosme Odabachian, OncBioMune’s General Manager of Global Operations. “I believe that if we can achieve our goal of commercializing Aagaard Propolis early in the third quarter that we have an opportunity to exceed US$1.0 million in total sales this year while maintaining strong margins. I am confident that we are going to become a leading pharma throughout Central and South America with our aggressive marketing and licensing strategy that will backstop our clinical work with ProscaVax in Mexico and the United States.”
The company recently announced that sales in Mexico of the Company’s licensed products, Bekunis for constipation and Cirkused for stress, exceeded projections during the first six months on the market.
Sales from September 16, 2016 to February 16, 2017 were approximately US$330,000, exceeding projections for US$125,000 initially forecast for the first six months at product launch during the third quarter last year. The Company anticipates that sales efforts will continue to accelerate and anticipates combined sales in the range of US$750,000 to US$850,000 for the products in 2017.
That’s way ahead of market assumptions and could fuel a major charge higher in the stock. The company recently made another similar move, announcing the signing of a licensing agreement between the Company and PROCAPS S.A.S. granting OncBioMune rights to tretinoin, also known as all-trans retinoic acid (ATRA), an oral drug for the treatment of Acute Promyelocytic Leukemia (APL), throughout Mexico, Central America and Latin America. That will add yet another revenue-generating horse to the stable.
Finally, and most recently, as noted above, the company just announced the completion of enrollment for its phase I for ProscaVax.
“We are very pleased to have reached this milestone to complete the first clinical trial of ProscaVax,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “The interim data to date has been extremely compelling, demonstrating the strong safety and tolerability profile of ProscaVax, as well as indications of efficacy with respect to slowing tumor progression and supporting an immune response to disease. Based upon the data and years of previous research, we remain optimistic that ProscaVax has a future as a meaningful therapeutic for the millions of people affected by prostate cancer.”
